Skip to content

Comparison of efficacy of two insulin regimens in Patients of Acute Stroke with hyperglycemia

Randomized Controlled Trial comparing Efficacy of Basal Bolus Insulin Vs Sliding Scale Insulin Regimen in Patients with Acute Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/017919
Enrollment
256
Registered
2019-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I639- Cerebral infarction, unspecified

Interventions

Intervention1: Human insulin: Basal bolus regimen Total dose-0.5 U/kg subcutaneous Half dose- Long acting Insulin once a day Half dose- Regular/ Rapid acting insulin in 3 divided doses before each me

Sponsors

Smruti Babtiwale
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Hospitalized patients with acute stroke presented within 7 days of event with hyperglycemia (Blood glucose > 140 mg/dL).

Exclusion criteria

Exclusion criteria: 1. Age 2. Pregnancy 3. Chronic liver or kidney disease 4. Patients on corticosteroids 5. RBS > 400mg/dL 6. Patients with Diabetic ketoacidosis 7. Not giving consent

Design outcomes

Primary

MeasureTime frame
To determine differences in the mean daily blood glucose concentration.Timepoint: To determine differences in the mean daily blood glucose concentration at the end of 3-5 days of hospital stay.

Secondary

MeasureTime frame
1.Differences between treatment groups in number of hypoglycemic events 2.Difference in modified Rankin Score (mRS) score at the time of evaluation and at 3 months follow up. 3.Mortality rate Timepoint: During admission and at 3 months of follow up

Countries

India

Contacts

Public ContactDr Smruti Babtiwale

All India Institute of Medical Sciences, New Delhi.

drkameshwarprasad@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026